LANREOTIDE

Brand name:

• Mytolac®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Acromegaly;
• Functional carcinoid tumour;
• Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET).

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (–)

Comment:

--

Submission sponsor:

AMDIPHARM MERCURY (AUSTRALIA) PTY LIMITED

Other PBAC consideration:

--

Submission received for:

November 2022 PBAC meeting

Opportunity for consumer comment:

Open 27/07/2022 and close 21/09/2022 (see PBS Website)

PBAC meeting:

Held on 02/11/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

12/12/2022

Lodgement of required documentation:

22/12/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 23/01/2023

Status:

Finalised

Government processes:

Commenced on 19/04/2023

Medicine listed on the PBS:

01/08/2023 (see PBS schedule)

---